Synonym
Iprazochrome; Divascan; NSC10065; NSC-10065; NSC 10065
IUPAC/Chemical Name
2-(1,2,3,6-Tetrahydro-3-hydroxy-1-(1-methylethyl)-6-oxo-5H-indol-5-ylidene)hydrazinecarboxamide
InChi Key
XZKVIDLLLOUTSS-ZSOIEALJSA-N
InChi Code
InChI=1S/C12H16N4O3/c1-6(2)16-5-11(18)7-3-8(14-15-12(13)19)10(17)4-9(7)16/h3-4,6,11,18H,5H2,1-2H3,(H3,13,15,19)/b14-8-
SMILES Code
O=C1/C(C=C2C(O)CN(C(C)C)C2=C1)=N\NC(N)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
264.29
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kozubski W, Prusiński A. Kontrolowane badania skuteczności iprazochromu (Divascan) w profilaktycznym leczeniu migreny [Controlled study of iprazochrome effectiveness (Divascan) in prophylactic treatment of migraine]. Neurol Neurochir Pol. 1999 Mar-Apr;33(2):369-76. Polish. PMID: 10463251.
2: Koch G. Iprazochrom in der Migräneprophylaxe. Keine Bedenken gegen längere Anwendung [Iprazochrome in migraine prevention. No concerns regarding longer- term administration]. Nervenarzt. 1997 Aug;68(8 Suppl Der Seroto):4. German. PMID: 9380219.
3: Fukawa K, Bando K, Hatanaka Y, Ohba S, Honda H, Saitoh K, Nakazato K, Irino O, Nagawa Y, Nagaoka A. [Pharmacological actions of iprazochrome on the vascular system]. Nihon Yakurigaku Zasshi. 1985 Jul;86(1):61-9. Japanese. doi: 10.1254/fpj.86.61. PMID: 4043870.
4: Wiedemann M, de Lima VM, Hanke W. Effects of antimigraine drugs on retinal spreading depression. Naunyn Schmiedebergs Arch Pharmacol. 1996 Apr;353(5):552-6. doi: 10.1007/BF00169175. PMID: 8740149.
5: Mustafa T, Srivastava KC. Ginger (Zingiber officinale) in migraine headache. J Ethnopharmacol. 1990 Jul;29(3):267-73. doi: 10.1016/0378-8741(90)90037-t. PMID: 2214812.
6: Nebenwirkungsarme Intervallbehandlung der Migräne. Der Serotonin-Antagonist Iprazochrom [Side-effect free interval treatment of migraine. The serotonin antagonist iprazochrome]. Nervenarzt. 1997 Aug;68(8 Suppl Der Seroto):1-3. German. PMID: 9380218.
7: Hampf G. Effect of serotonin antagonists on patients with atypical facial pain. J Craniomandib Disord. 1989 Fall;3(4):211-2. PMID: 2639158.
8: Osterman PO. Divascan in migraine prophylaxis. Open trial with three different doses. Headache. 1978 Sep;18(4):225-8. doi: 10.1111/j.1526-4610.1978.hed1804225.x. PMID: 721453.
9: Kochanowski J. Zapobiegawcze leczenie migreny [Prophylactic treatment of migraine]. Neurol Neurochir Pol. 1999;32 Suppl 6:75-80. Polish. PMID: 11107567.
10: Bekemeier H, Giessler AJ, Vogel E. Influence of MAO-inhibitors, neuroleptics, morphine, mescaline, divascan, aconitine, and pyrogenes on prostaglandin-biosynthesis. Pharmacol Res Commun. 1977 Jun;9(6):587-98. doi: 10.1016/s0031-6989(77)80087-8. PMID: 19774.
